<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002266</url>
  </required_header>
  <id_info>
    <org_study_id>045B</org_study_id>
    <secondary_id>753A-103-US</secondary_id>
    <nct_id>NCT00002266</nct_id>
  </id_info>
  <brief_title>An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients</brief_title>
  <official_title>An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times&#xD;
      per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or&#xD;
      AIDS related complex (ARC) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS-101</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Standard therapy for infections.&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Allowed only with permission of Wyeth-Ayerst medical monitor:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Specific therapy for malignancies (including Kaposi's sarcoma).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Evidence of severe liver dysfunction (serum albumin &lt; 3 g/dl, SGOT or SGPT &gt; 5 x upper&#xD;
             limit of normal, prothrombin time &gt; 15 seconds), or gastrointestinal, renal,&#xD;
             respiratory, endocrine, hematologic, cardiovascular system abnormalities or&#xD;
             psychiatric disorder other than abnormalities secondary to AIDS or AIDS related&#xD;
             complex (ARC).&#xD;
&#xD;
          -  Evidence of AIDS-related central nervous system involvement.&#xD;
&#xD;
          -  Disseminated Kaposi's sarcoma.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded without permission of Wyeth-Ayerst medical monitor:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Specific therapy for malignancies (including Kaposi's sarcoma).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Evidence of major system abnormalities other than abnormalities secondary to AIDS or&#xD;
             AIDS related complex.&#xD;
&#xD;
          -  Concomitant conditions as specified in Patient Exclusion Co-existing Conditions.&#xD;
&#xD;
          -  Unlikely or unable to comply with the requirements of the protocol.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Systemic antiviral agents.&#xD;
&#xD;
          -  Immunosuppressive agents.&#xD;
&#xD;
          -  Immune stimulators such as BCG vaccine, isoprinosine, or other immunomodulators.&#xD;
&#xD;
        Patients must:&#xD;
&#xD;
          -  Have a diagnosis of AIDS or AIDS related complex (ARC).&#xD;
&#xD;
          -  Demonstrate intolerance or refusal to take zidovudine (AZT).&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Arizona / Health Science Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>ammonium trichloro(dioxoethylene-O,O'-)tellurute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ammonium trichloro(dioxoethylene-O,O'-)tellurate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

